Darin Lippoldt is CLO at NEUROCRINE BIOSCIENCES INC (NBIX). They have made 35 open-market trades across 1 company since 2012, most recently 2026-09-11.
CIK 0001504783
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 35 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NBIX | SELL · 10b5-1 | 2026-07-09 | 2026-07-13 | $179.60 | $1.8M | +1.5% | -8.9% | -17.7% |
| NBIX | SELL · 10b5-1 | 2026-06-26 | 2026-06-30 | $170.15 | $1.7M | +3.2% | +10.2% | -16.7% |
| NBIX | SELL · 10b5-1 | 2025-12-08 | 2025-12-10 | $159.65 | $1.4M | -3.8% | -11.5% | -15.3% |
| NBIX | SELL · 10b5-1 | 2025-02-13 | 2025-02-14 | $116.75 | $510K | +2.2% | -3.1% | +4.6% |
| NBIX | SELL · 10b5-1 | 2025-02-10 | 2025-02-12 | $118.25 | $215K | -1.2% | -5.6% | -0.4% |
| NBIX | SELL · 10b5-1 | 2025-01-31 | 2025-02-04 | $152.91 | $382K | -24.2% | -25.7% | -27.6% |
| NBIX | SELL · 10b5-1 | 2024-08-01 | 2024-08-05 | $154.01 | $923K | +0.0% | -17.0% | -18.4% |
| NBIX | SELL · 10b5-1 | 2024-07-16 | 2024-07-18 | $150.00 | $1.1M | -2.3% | +2.6% | -18.1% |
| NBIX | SELL · 10b5-1 | 2024-02-13 | 2024-02-15 | $132.99 | $292K | +0.4% | +3.9% | +5.9% |
| NBIX | SELL · 10b5-1 | 2024-02-06 | 2024-02-08 | $138.47 | $541K | -3.0% | +2.9% | +3.2% |
| NBIX | SELL · 10b5-1 | 2024-01-31 | 2024-02-02 | $140.65 | $352K | -6.7% | -5.7% | -1.0% |
| NBIX | SELL · 10b5-1 | 2024-01-22 | 2024-01-24 | $139.86 | $2.8M | +0.5% | -4.9% | -0.7% |
| NBIX | SELL · 10b5-1 | 2023-12-06 | 2023-12-08 | $119.86 | $5.0M | +2.6% | +14.3% | +15.5% |
| NBIX | SELL · 10b5-1 | 2023-11-27 | 2023-11-29 | $112.27 | $2.5M | +3.9% | +15.6% | +19.3% |
| NBIX | SELL · 10b5-1 | 2023-08-21 | 2023-08-23 | $107.39 | $458K | +2.1% | +5.6% | +1.8% |
| NBIX | SELL | 2023-02-06 | 2023-02-08 | $102.71 | $3.3M | -2.5% | -8.5% | -7.2% |
| NBIX | SELL | 2023-01-31 | 2023-02-02 | $109.97 | $275K | -5.8% | -7.8% | -9.8% |
| NBIX | SELL | 2022-11-08 | 2022-11-10 | $125.04 | $1.3M | -1.7% | -2.8% | -15.0% |
| NBIX | SELL | 2022-11-03 | 2022-11-04 | $125.02 | $1.1M | -7.7% | +1.6% | -11.5% |
| NBIX | SELL | 2022-11-01 | 2022-11-02 | $120.28 | $1.3M | -3.2% | +4.0% | -9.0% |
| NBIX | SELL | 2022-10-26 | 2022-10-28 | $115.03 | $2.3M | +7.2% | +6.6% | -5.0% |
| NBIX | SELL | 2022-10-04 | 2022-10-05 | $111.04 | $1.1M | +2.3% | +12.2% | +10.6% |
| NBIX | SELL | 2022-03-18 | 2022-03-22 | $95.05 | $1.6M | +1.5% | +1.7% | -0.8% |
| NBIX | SELL | 2022-02-07 | 2022-02-09 | $80.44 | $608K | +10.7% | +12.7% | +3.8% |
| NBIX | SELL | 2021-02-05 | 2021-02-09 | $116.20 | $5.8M | -4.3% | -18.5% | -21.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.